Home › Entities › clinical_trial › DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2

DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2

clinical trial
MedicalStudy clinical_trial Q64807536
Press Enter · cited answer in seconds

DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2

Summary

DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2 is a clinical trial[1].

Key Facts

  • DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2 is in the country of Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2 — country (P17): Netherlands[2].
  • DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2's instance of is recorded as Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2 — instance of (P31): clinical trial[3].
  • DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2's start time is recorded as +2017-09-18T00:00:00Z[4].
  • DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2's end time is recorded as +2020-01-31T00:00:00Z[5].
  • DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2's sponsor is recorded as Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2 — sponsor (P859): VU University Medical Center[6].
  • DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2's main subject is recorded as Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2 — main subject (P921): diabetes[7].
  • DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2's number of participants is recorded as {'unit': '1', 'amount': '+64'}[8].
  • DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2's title is recorded as Combined Effects of SGLT2 Inhibition and GLP-1 Receptor Agonism on Food Intake, Body Weight and Central Satiety and Reward Circuits in Obese T2DM Patients[9].
  • DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2's short name is recorded as DECREASE[10].
  • DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}[11].
  • DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2's ClinicalTrials.gov ID is recorded as NCT03361098[12].
  • DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+75'}[13].
  • DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2's research intervention is recorded as Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2 — research intervention (P4844): glucagon-like peptide-1 agonist[14].
  • DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2's research intervention is recorded as Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2 — research intervention (P4844): exenatide[15].
  • DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2's clinical trial phase is recorded as Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2 — clinical trial phase (P6099): phase IV clinical trial[16].
  • DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2's study type is recorded as Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2 — study type (P8363): interventional study[17].

References

Programmatic citations — every numbered marker resolves to a verifiable graph row below.

Direct Wikidata claims

  1. [2] ↑ . wikidata.org.
  2. [3] ↑ . wikidata.org.
  3. [4] ↑ . wikidata.org.
  4. [5] ↑ . wikidata.org.
  5. [6] ↑ . wikidata.org.
  6. [7] ↑ . wikidata.org.
  7. [8] ↑ . wikidata.org.
  8. [9] ↑ . wikidata.org.
  9. [10] ↑ . wikidata.org.
  10. [11] ↑ . wikidata.org.
  11. [12] ↑ . wikidata.org.
  12. [13] ↑ . wikidata.org.
  13. [14] ↑ . wikidata.org.
  14. [15] ↑ . wikidata.org.
  15. [16] ↑ . wikidata.org.
  16. [17] ↑ . wikidata.org.

Class ancestry

  1. [1] ↑ . Wikidata. wikidata.org.

📑 Cite this page

Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.

APA 4ort.xyz Knowledge Graph. (2026). DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2. Retrieved May 3, 2026, from https://4ort.xyz/entity/decrease-dapagliflozin-plus-exenatide-on-central-regulation-of-appetite-in-diabetes-type-2
MLA “DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2.” 4ort.xyz Knowledge Graph, 4ort.xyz, 3 May. 2026, https://4ort.xyz/entity/decrease-dapagliflozin-plus-exenatide-on-central-regulation-of-appetite-in-diabetes-type-2.
BibTeX @misc{4ortxyz_decrease-dapagliflozin-plus-exenatide-on-central-regulation-of-appetite-in-diabetes-type-2_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2}}, year = {2026}, url = {https://4ort.xyz/entity/decrease-dapagliflozin-plus-exenatide-on-central-regulation-of-appetite-in-diabetes-type-2}, note = {Accessed: 2026-05-03}}
LLM prompt According to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2 — https://4ort.xyz/entity/decrease-dapagliflozin-plus-exenatide-on-central-regulation-of-appetite-in-diabetes-type-2 (retrieved 2026-05-03)

Canonical URL: https://4ort.xyz/entity/decrease-dapagliflozin-plus-exenatide-on-central-regulation-of-appetite-in-diabetes-type-2 · Last refreshed: